Open AccessClostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
Author(s) -
Edward V. Loftus,
Daniel C. Baumgart,
Krisztina Gecse,
Jami Kinnucan,
Susan B. Connelly,
Leonardo Salese,
Chinyu Su,
Kenneth Kwok,
John Woolcott,
Alessandro Armuzzi
Publication year - 2022
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izac139
Subject(s) - tofacitinib , medicine , ulcerative colitis , janus kinase inhibitor , inflammatory bowel disease , gastroenterology , clostridium difficile , placebo , incidence (geometry) , discontinuation , cohort , surgery , disease , antibiotics , rheumatoid arthritis , physics , alternative medicine , optics , pathology , microbiology and biotechnology , biology
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Patients with inflammatory bowel disease are susceptible to Clostridium difficile infection (CDI). Here, we evaluate CDI in the tofacitinib UC clinical program.